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ABSTRACT
Base damage and topoisomerase I (Top1)-linked
DNA breaks are abundant forms of endogenous
DNA breakage, contributing to hereditary ataxia
and underlying the cytotoxicity of a wide range of
anti-cancer agents. Despite their frequency, the
overlapping mechanisms that repair these forms of
DNA breakage are largely unknown. Here, we report
that depletion of Tyrosyl DNA phosphodiesterase 1
(TDP1) sensitizes human cells to alkylation damage
and the additional depletion of apurinic/apyrimidinic
endonuclease I (APE1) confers hypersensitivity
above that observed for TDP1 or APE1 depletion
alone. Quantification of DNA breaks and clonogenic
survival assays confirm a role for TDP1 in response
to base damage, independently of APE1. The hyper-
sensitivity to alkylation damage is partly restored by
depletion of Top1, illustrating that alkylating agents
can trigger cytotoxic Top1-breaks. Although inhib-
ition of PARP activity does not sensitize TDP1-
deficient cells to Top1 poisons, it confers increased
sensitivity to alkylation damage, highlighting par-
tially overlapping roles for PARP and TDP1 in
response to genotoxic challenge. Finally, we dem-
onstrate that cancer cells in which TDP1 is inher-
ently deficient are hypersensitive to alkylation
damage and that TDP1 depletion sensitizes
glioblastoma-resistant cancer cells to the alkylating
agent temozolomide.
INTRODUCTION
It is becoming clear that human cells use distinct but func-
tionally overlapping pathways to protect the genome from
internal and external insults. Base damage and abasic
(apurinic or apyrimidinic) sites ‘AP sites’ are common
forms of DNA lesions that constitute 104 lesions per
cell per day (1). Base damage can be triggered endogen-
ously in living cells as a result of base oxidation or
from cofactors of biochemical reactions such as
S-adenosylmethionine (2). Base damage can also result
from the exposure to external alkylating agents such as
fuel combustion products and tobacco smoke (3,4). AP
sites are generated by the spontaneous or enzymatic hy-
drolysis of the N-glycosylic bond linking the damaged
base to the deoxyribose sugar (5). The latter is conducted
by monofunctional DNA glycosylases to remove damaged
bases during base excision repair (BER) (6). AP sites can
block progression of DNA and RNA polymerases, and if
bypassed by translesion polymerases could result in base
substitution and mutations (7,8). AP endonuclease 1
(APE1) maintains genetic integrity by hydrolysing the de-
oxyribose backbone at the 50-side of the AP site, resulting
in a nick with a 30-hydroxyl and 50-deoxyribose phosphate
(50-dRP), which are further processed by the short-patch
or long-patch base excision repair [reviewed in (9,10)].
Cleavage of AP sites can also occur at the 30-side
through a b- or d-elimination reaction initiated by dual
function DNA glycosylases/lyases, resulting in a nick with
30-a,b-unsaturated aldehyde (11,12). The resulting ‘dirty’
30- and 50-DNA termini are restored to conventional
30-hydroxyl and 50-phosphate by a variety of DNA end-
processing activities such as the 50-dRP lyase activity of
DNA polymerase b (Pol b), the endonuclease activity
of ﬂap endonuclease 1 or the phosphatase/kinase activity
of polynucleotide kinase phosphatase [recently reviewed
in (13)].
In addition to base damage and AP sites, another form
of DNA lesion features proteins linked to DNA termini.
It can arise during the normal enzymatic cycles of DNA
topoisomerases where they form transient covalent
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linkage with the 30-terminus of DNA (e.g. topoisomerase I
‘Top1’) or with the 50-terminus (e.g. topoisomerase II
‘Top2’). These normal enzymatic cycles become abortive
if the transient topoisomerase-DNA complex collides with
DNA or RNA polymerases or in the presence of adjacent
nicks, gaps or DNA secondary structures. Cells use spe-
ciﬁc enzymatic activities with distinct polarities to hydro-
lyze the covalent linkage between the stalled
topoisomerase and DNA. This is typiﬁed by tyrosyl
DNA phosphodiesterase 1 and 2 (TDP1 and TDP2),
which remove Top1 and Top2 linked DNA breaks, re-
spectively. The phosphodiesterase activity of TDP1 has
also been implicated in processing other types of
blocking 30-lesions such as 30-phosphoglycolates [recently
reviewed in (14)]. More recently, biochemical studies using
recombinant protein and cellular studies in
Schizosaccharomyces pombe and chicken DT40 cells have
suggested a role for TDP1 in processing AP sites and
30dRP lesions (15–17). However, whether TDP1 protects
human cells from base damage and the mechanisms by
which it exerts this function are unknown. Here, using
human MRC5 cells and cancer cell lines inherently deﬁ-
cient for TDP1 or resistant to alkylation-based chemo-
therapy, we show that TDP1 deﬁciency sensitizes human
cells to base damage, independently of APE1. Top1 deple-
tion alleviated the hypersensitivity to base damage,
illustrating that alkylation-induced cytotoxicity is partly
dependent on Top1. TDP1 promotes the repair of both
Top1- and AP/30-dRP lesions induced by alkylating agents
via its tyrosyl DNA phosphodiesterase and AP/30dRP
lyase activities. Although the former is PARP dependent,
the latter is PARP independent, pointing at new clinical
settings for the emerging applications of PARP inhibitors.
MATERIALS AND METHODS
Cell culture and transfection
Human MRC5, DLD1, T98G, U87 cells were grown in
minimum essential medium (Gibco) supplemented with
10% foetal bovine serum (PAA), 2mM L-glutamine, 100
unit/ml penicillin and 100U/ml streptomycin (Gibco)
(18,19). RKO cells were grown in RMPI medium supple-
mented with 10% foetal bovine serum, 2mM L-glutamine,
100U/ml penicillin and 100U/ml streptomycin. MRC5
cells were infected with MissonTM lentivirus particles
(Sigma) containing shRNA targeting human TDP1 (50-C
CGGGCACGATCTCTCTGAAACAAACTCGAGTTT
GTTTCAGAGAGATCGTGCTTTTTG-30) or with
GIPZ lentivirus particles (Thermo) containing shRNA
targeting human topoisomerase I (50-CCAGAGAATGT
CAAGTTTT-30). Control ‘non target’ shRNA lentivirus
particles were used as a control (Sigma). Infection was
conducted for 16 h in opti-MEM (Serum free, Gibco)
without antibiotic followed by addition of fresh
complete medium for 24 h. Stably infected cells were main-
tained in 1ug/ml puromycin (Sigma). APE1, TDP1 or
Top1 transient knockdown was achieved using ON-
TARGETplus Smart pool from Dharmacon. Sequences
for TDP1 (CUAGACAGUUUCAAAGUGA, GACCA
UAUCUAGUAGUGAU, UCAGUUACUUGAUGGC
UUA, GGAGUUAAGCCAAAGUAUA), for Top1 (G
AAAAUGGCUUCUCUAGUC, GAUUUCCGAUUG
AAUGAUU, GCACAUCAAUCUACACCCA, CGAA
GAAGGUAGUAGAGUC), for APE1 (CAAAGUUUC
UUACGGCAUA, GAGACCAAAUGUUCAGAGA, C
UUCGAGCCUGGAUUAAGA, UAACAGCAUAUG
UACCUAA). Cells maintained in suspension at 2 104
per 6-cm dish were transfected with 20 pM/ml siRNA in
serum-free medium (Opti-MEM) containing Metafecten
(Cambio). To improve knockdown efﬁciency, a second
round of transfection was conducted after 24 h.
Knockdown efﬁciency was determined 48–72 h after trans-
fection using immunoblotting. For ectopic overexpression
of TDP1 and APE1 in MRC5, cells grown to 50%
conﬂuency on 60-cm dishes were transfected with 1 mg
empty mammalian expression construct or 1 mg of
plasmids encoding human Myc-tagged TDP1, human
Flag-tagged APE1 or both, using Metafecten transfection
reagent (Cambio). Expression of the fusion proteins
was analyzed 24 h following transfection and survival
was conducted on the same samples used to assess
protein expression, as described earlier in text.
Chicken DT40 cells, were cultured a 39C and 5% CO2
in RPMI 1640 supplemented with 10% FCS, 1% chicken
serum, 2mM l-glutamine, 100U/ml penicillin and 100 mg/
ml streptomycin with 105 b-Mercaptoethanol. DT40
Tdp1/ cells were described previously (20). For the gen-
eration of stable Tdp1/ cells expressing human TDP1,
5 mg of linearized pCD2E vector containing G418 resist-
ance cassette and 15 mg of linearized Myc-tagged hTDP1
(21) or empty vector were mixed with 5 106 cells in
0.5ml ice-cold PBS. Samples were then transferred to a
Gene Pulser cuvette (Bio-Rad) with a 0.4-cm electrode gap
and left for 10min at 4C, using the Bio-Rad Gene Pulser.
Samples were then electroporated at 550V and 25 mFD
and chilled on ice for 10min. Cells were then transferred
to a 10-cm dish containing 20ml pre-warmed complete
medium and left overnight at 39C. Cells were diluted in
80ml media supplemented with 2mg/ml G418 for selec-
tion and aliquoted into 200 ml samples in 4 96-well
plates. Cells were then left for 7 days until colonies
became visible. Approximately 2mm diameter cells were
transferred to 24-well plates with 1.5ml of pre-warmed
medium and left until they reached 100% conﬂuency
(3 days). Cells were then harvested and samples analyzed
for stable clones by anti-Myc immunoblotting.
Immunoblotting
Cells were lysed in 50mM Tris–HCl, 500mM NaCl,
2mM EDTA, 2mM EGTA, 25mM NaF, 25mM
b-glycerolphosphate, 0.1mM NaOrthovanadate, 0.2%
Triton X-100, 0.3% NP-40, 10U/ml of Benzonase nucle-
ase and protease inhibitor cocktail (Roche) for 1 h at 4C.
Cellular debris was removed by centrifugation at
13 000 rpm for 15min. Total protein concentration was
determined by Bradford Assay, and equal concentrations
were separated by 10% SDS–PAGE and transferred to
nitrocellulose membranes. Membranes were blocked in
6% non-fat dry milk and incubated with primary
antibodies overnight at 4C. Horse-radish peroxidase
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(HRP)-conjugated secondary antibodies were incubated
for 1 h at room temperature, and membranes were de-
veloped with enhanced chemiluminescence (Western
lightening Plus-ECL, Perkin Elmer). Primary antibodies
used were rabbit polyclonal anti-Tdp1 (1:500; MW:
75 kDa) developed in the laboratory by Eurogentec
using TDP1151608 as an antigen, mouse monoclonal
anti-Top1 (1:1000; MW: 100 kDa) from Santa Cruz bio-
technology (sc-32736), rabbit polyclonal anti-APE1
(1:1000; MW:37 kDa) from Novus Biologicals
(NB100–101), anti-Tubulin (1:3000; MW: 55 kDa)
from Abcam (ab4074), anti-MGMT (1:1000;
MW:25 kDa) from Abcam (ab7045), anti-Myc (1:4000;
9B11; cell signalling), anti-PCNA (1:2000; MW: 29 kDa)
from Alan Lehmann and anti-Actin (1:3000;
MW:42 kDa) from Sigma-Aldrich (a3853). HRP-
conjugated secondary antibodies were from Dako
(1:3000; P0260 and P0448).
Clonogenic survival and viability assays
Cells were plated in 10-cm dishes in duplicate and
mock-treated with DMSO or with the indicated doses
of camptothecin (CPT; Sigma) for 1 h, methyl metha-
nesulfonate (MMS; Sigma) for 15min, Temozolomide
(TMZ; Sigma) at 37C. Where indicated, cells were pre-
incubated with 150 mM APE1 inhibitor CRT0044876
(Sigma) for 90min (MRC5) or 120min (cancer cell lines)
or with 1 mM PARP inhibitor Olaparib for 60min. Cells
were washed 1 with phosphate-buffered saline and 2
with complete medium. Cells were then allowed to grow
for 7–10 days until the formation of macroscopic colonies.
Colonies were ﬁxed in 80% cold ethanol and stained with
1% methylene blue. Survival was calculated by dividing
the average number of colonies on treated plates by the
average number of colonies on untreated plates. Data are
the mean±s.e.m. of three biological replicates.
DT40 cells (0.5ml; 1 105 cells in 10ml) were mixed
with 0.5ml media containing increasing concentrations
of CPT or MMS in the presence or absence of 0.5 mM
PARP inhibitor Olaparib. Five hundred cells/well were
seeded in triplicate into 96-well plates with 100 ml of
medium/well. Plates were incubated at 39C for 72 h and
cell viability determined using the CellTiter-Blue kit
(Promega). Brieﬂy, 20 ml of CellTiter-Blue reagent was
added to each well and ﬂuorescence was measured at
560 nm Ex/590 nm Em using GloMax-Multi Detection
System (Promega) and data analyzed using SigmaPlot.
Viability of untreated cells was set to 100% and error
bars represent standard error from three independent
biological repeats.
Alkaline single-cell agarose gel electrophoresis assays
Cells were incubated with the indicated doses of CPT for
60min or MMS for 15min at 37C. DNA strand breakage
[primarily DNA single-strand breaks (SSBs) and alkali
labile sites]were quantiﬁed by alkaline comet assays essen-
tially as described (22). Brieﬂy, cells were suspended in
pre-chilled phosphate buffered saline (PBS) and mixed
with equal volume of 1.2% low-gelling-temperature
agarose (Sigma, Type VII) maintained at 42C. Cell
suspension was immediately layered onto pre-chilled
frosted glass slides (Fisher) pre-coated with 0.6%
agarose and maintained in the dark at 4C until set, and
for all further steps. Slides were immersed in pre-chilled
lysis buffer [2.5M NaCl, 10mM Tris–HCl, 100mM
ethylenediaminetetraacetic acid (EDTA) (pH 8.0), 1%
Triton X-100 and 1% dimethylsulfoxide (DMSO); (pH
10)] for 1 h, washed with pre-chilled distilled water
(2 10min) and placed for 45min in pre-chilled alkaline
electrophoresis buffer (50mM NaOH, 1mM EDTA and
1% DMSO). Electrophoresis was then conducted at 1V/
cm for 25min, followed by neutralization in 400mM Tris–
HCl (pH 7.0) for 1 h. Finally, DNA was stained with Sybr
Green I (1:10 000 in PBS) for 30min. Average tail
moments from 50 cells/sample were measured using
Comet Assay IV software (Perceptive Instruments, UK).
Data are the average±s.e.m from three independent
experiments. Statistical analyses were conducted using
student t-test.
Measurement of global RNA transcription
MRC5 cells were grown on coverslips for 48–72 h in
complete media deprived of serum. The Click-iT RNA
Alaxa Flour 488 Kit (Invitrogen) was used according to
manufacture’s instructions to quantify global RNA tran-
scription. Brieﬂy, cells were treated with the indicated
doses of CPT for 1 h or with MMS for 15min and either
harvested immediately after treatment or washed twice
with serum-free medium and incubated in drug-free
medium for a subsequent 3 h to allow for transcription
recovery. Cells were incubated with 0.1mM 5-ethynl
uridine (EU) for 30min in presence or absence of CPT
or MMS to label newly synthesized RNA. Cells were
washed with PBS, ﬁxed with 3.7% formaldehyde for
15min and permeabilized with 0.5% Triton-X100 for
20min at room temperature. Cells were then incubated
with Click iT reaction cocktail containing Click-iT
additive and Alexa Flour azide 488 for 30min at 37C.
Following washing with PBS containing 3% BSA, cells
were mounted on glass slides using a DAPI containing
antifade medium. RNA labeled with EU was then sub-
jected to immunoﬂuorescence analyses. Average ﬂuores-
cence signal was quantiﬁed from 200 to 300 cells using
Corel Photo Draw software.
RESULTS
To examine the role of TDP1 in response to DNA alkyl-
ation damage, we generated human MRC5 cells in which
endogenous level of TDP1 was stably depleted using
shRNA. TDP1 expression in cells infected with TDP1
shRNA was reduced by 90% compared with cells
infected with control shRNA (Figure 1a). Consistent
with a role for TDP1 in repairing Top1-mediated DNA
damage, TDP1-depleted cells (TDP1KD) were more sensi-
tive than controls to the Top1 poison camptothecin (CPT)
(Figure 1b). To test whether TDP1 depletion confers
hypersensitivity to base damage, we incubated control
and TDP1KD cells with increasing concentrations of the
alkylating agent methyl methanesulfonate (MMS). MMS
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induced a dose-dependent killing in both cell lines, but cell
death in TDP1KD was signiﬁcantly higher (P< 0.05;
Figure 1c), illustrating a role for TDP1 in protecting
human cells from base damage.
AP endonuclease I (APE1) is the major nuclease for
excising abasic sites resulting from alkylation damage,
and thus plays a key role in protecting human cells from
this type of DNA breakage. To test whether TDP1 func-
tions together in the same pathway as APE1, we transi-
ently depleted APE1 in control and in TDP1KD cells using
siRNA and compared the ability of cells to survive MMS
damage. Consistent with published data (23–25), depletion
of 90% of cellular APE1 (Figure 2a) led to 10-fold
reduction of the cellular resistance to MMS (Figure 2b).
Notably, co-depletion of APE1 and TDP1 led to enhanced
cell sensitization to MMS above that observed for deple-
tion of TDP1 or APE1 alone, suggesting that TDP1
operates in a parallel pathway to APE1, to repair MMS-
induced DNA damage. This was further conﬁrmed by
pharmacological inhibition of APE1 repair activity using
CRT0044876 (26,27) (Figure 2c). These observations
are consistent with cellular studies in S. pombe where
tdp1apn2 double mutant cells showed synergistic
increase in MMS sensitivity compared with single
mutants (16). To test whether the lyase (either AP,
30-dRP or both) activity of TDP1 could explain, at least
in part, the sensitivity of TDP1KD cells to MMS, we
measured DNA strand breaks and abasic sites using
alkaline single-cell gel electrophoresis (comet assays). We
postulated that the monofunctional alkylating agent
MMS would produce base alkylation, which would
undergo spontaneous or glyosylase-mediated base release
to generate cytotoxic abasic sites. The alkaline nature of
the comet assay would uncover abasic sites resulting from
defects in APE1 or TDP1. Similarly, processing of AP
sites in cells and generation of 30-dRP lesions would also
result in detectable SSBs by the alkaline comet assay. As
predicted, depletion of APE1 led to 2.5-fold increase of
SSBs (Figure 2d). Although depletion of TDP1 led to an
increase of MMS-induced SSBs, co-depletion of TDP1
and APE1 led to higher number of SSBs than depletion
of either enzyme alone.
It is worth noting that 30-dRP lesions are more cytotoxic
than AP sites, and thus more likely to account for the
survival data (Figure 2b), as they would not be bypassed
by translesion polymerases. We, therefore, hypothesized
that overexpression of APE1 would generate excessive
toxic intermediates that exceeds the ability of downstream
repair factors to deal with, causing cellular hypersensitiv-
ity to MMS. If it is true that TDP1 protects from APE1-
induced lesions, either directly or indirectly, then its
overexpression would confer protection. To test this
hypothesis, we generated MRC5 cells in which APE1
and TDP1 were ectopically overexpressed separately or
together, and compared their sensitivity to MMS (Figure
3a). APE1 overexpression sensitized MRC5 cells to MMS,
which is consistent with published work (28) and, import-
antly, increasing the cellular pool of TDP1 offered a re-
markable protection (Figure 3b and Supplementary
Figure S1). Together, these data demonstrate that TDP1
protects human cells from MMS damage.
(a) kDa 
75 
100 
42 
TDP1 
Actin 
Top1 
WT TDP1KD 
(b)
0.00 
0.01 
0.10 
1.00 
0 5 10 15 20
Su
rv
iva
l (%
) 
CPT (µM) 
WT 
TDP1KD 
(c)
0.00 
0.01 
0.10 
1.00 
0 0.25 0.5 0.75 
MMS (µg/ml) 
Su
rv
iva
l (%
) 
WT 
TDP1KD 
*
*
*
*
Figure 1. TDP1 promotes the repair of alkylation-induced base
damage in human cells. (a) Human MRC5 cells were infected with
lentivirus particles containing non-targeting control shRNA ‘WT’ or
shRNA against human TDP1 ‘TDP1KD’. Cell lysates were fractionated
by SDS–PAGE and analyzed by immunoblotting using anti-TDP1
(Eurogentec), anti-Top1 (Santa Cruz) or anti-actin (Sigma) immuno-
blotting. (b) WT or TDP1KD MRC5 cells were incubated with the
indicated concentrations of camptothecin ‘CPT’ for 60min at 37C
and the ability of single cells to form macroscopic colonies was
determined by dividing the average number of colonies on treated
plates by the average number of colonies on untreated plates and pre-
sented as percentage survival. Data are the mean±s.e.m. of three bio-
logical replicates. (c) Survival was determined in WT and TDP1KD
MRC5 cells following exposure to the indicated doses of the alkylating
agent methyl methanesulfonate (MMS) for 15min at 37C as described
in (a). Data are the mean±s.e.m. of three biological replicates.
Asterisks denote statistically signiﬁcant difference between WT and
TDP1KD (P=0.04, 0.001, 0.02, 0.002 for MMS doses 0.1, 0.25, 0.5
and 0.75 mg/ml, respectively; t-test).
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How does TDP1 fulﬁl cellular protection from alkyl-
ation damage? DNA nicks and gaps have been shown to
trap Top1 on DNA resulting in Top1 single-strand breaks
(Top1-SSBs), and the ability of TDP1 to process these
structures (29) may contribute to its protective role in
response to MMS. To test whether this is the case,
we generated human cells in which TDP1 and Top1
were depleted separately or together (Figure 4a). We
ﬁrst examined the accumulation of Top1-SSBs following
exposure to CPT (Figure 4b). TDP1KD cells accumulated
5-fold more Top1-SSBs than control cells while
additional depletion of Top1 prevented their accumula-
tion (Figure 4b). Furthermore, Top1 depletion protected
TDP1KD cells from cell death induced by CPT to levels
comparable with those observed in control cells
(Figure 4c). We noted, however, that depletion of Top1
did not fully protect TDP1KD cells from CPT as it did
for control cells. We reasoned this may be due to
25% residual Top1 expression in Top1KD/TDP1KD
double mutants compared with almost complete Top1 de-
pletion in single Top1KD cells (Figure 4a). Additional de-
pletion of Top1 using siRNA led to marked reduction of
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Figure 2. Human cells depleted for TDP1 and APE1 exhibit synergistic hypersensitivity to MMS. (a) WT or TDP1KD MRC5 cells were subjected to
control non-targeting siRNA ‘Mock’ or siRNA against human APE1. Cell extract was fractionated by SDS–PAGE and analyzed by immunoblotting
using anti-APE1 antibodies (Novus). (b) Control human MRC5 ‘WT’, TDP1KD, APE1KD or cells depleted for both APE1 and TDP1 ‘TDP1KD
APE1KD’ were incubated with the indicated concentrations of MMS and percentage survival calculated from three independent replicates. Data are
the mean±s.e.m. Asterisks denote statistical difference (P< 0.01, t-test) between APE1KD and TDP1KD APE1KD cells (c) WT and TDPKD cells were
incubated with DMSO or 150mM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h followed by an additional incubation with the indicated
concentrations of MMS for 15min at 37C. Cell survival was calculated from the average of three independent experiments± s.e.m. Asterisks denote
statistical difference (P< 0.02; t-test) between mock and APEi-treated TDP1KD cells (d) MRC5 cells were incubated with the indicated doses of MMS
for 15min at 37C and DNA SSBs and alkali labile sites quantiﬁed by alkaline comet assays. Average tail moment from 50 cells/sample was
measured using Comet Assay IV software (Perceptive) and data are the average±s.e.m. of three independent experiments. Asterisks denote stat-
istical difference (P< 0.05; t-test) between APE1KD and TDP1KD APE1KD cells.
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Top1 expression (Figure 4d) and increased the CPT resist-
ance of Top1KD/TDP1KD double mutants to levels
observed in single Top1KD cells (Figure 4e).
Having now established a cellular system to speciﬁcally
study Top1-SSBs in response to genotoxic stress, we next
examined their contribution to the cytotoxicity conferred
by MMS. To our surprise, depletion of Top1 conferred
remarkable protection in TDP1KD cells from MMS
damage (Figure 5a), suggesting that Top1-breaks contrib-
ute to MMS-induced cytotoxicity. If it is true that MMS
induces Top1-breaks, then persistent exposure to MMS
would result in Top1 degradation similar to persistent
exposure to CPT. Incubation of MRC5 cells with CPT or
MMS led to signiﬁcant depletion of Top1 (Figure 5b). As is
the case for Top1 poisons, MMS-induced Top1 degrad-
ation was largely dependent on transcription since pre-
incubation with two different transcription inhibitors
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB)
or a-amanitin largely reduced or ablated Top1 degradation
(Figure 5c). Together, these data suggest that alkylation
damage generates transcription-associated Top1-breaks,
which contributes to TDP1’s protective role in response
to MMS.
As DNA nicks, gaps and Top1-breaks are predicted to
block progression of elongating RNA polymerases, we
next examined whether the protective role conferred by
TDP1 in response to alkylation damage can be explained
by its role during transcription. For these experiments, we
ﬁrst examined transcription competence following CPT in
serum-arrested human cells, to minimize the impact of
DNA replication. Incubation of control cells with CPT
led to remarkable reduction of global transcription,
which was restored to background levels following subse-
quent incubation in CPT-free media (Figure 6a).
Consistent with a role for TDP1 to repair transcription-
blocking Top1-breaks (21), its depletion led to a reduction
in transcription that failed to recover during 2 h incuba-
tion in CPT-free media (Figure 6b, c). Importantly, tran-
scription decline in these experiments was owing to
Top1-DNA breaks because Top1-depeletion ablated the
CPT-induced transcription decline.
We next examined transcription recovery following
MMS. Similar to CPT, incubation of control cells with
MMS reduced global transcription, which was restored
to background levels following incubation in MMS-free
media. Interestingly and consistent with a role for TDP1
in response to alkylation damage, TDP1-deﬁcient cells
failed to restore background transcription levels following
MMS (Figure 6d). However, in striking contrast to CPT,
MMS treatment of Top1-deﬁcient cells (Top1KD) also led
to a comparable reduction in transcription to that
observed in Top1 proﬁcient cells, suggesting that MMS
induces transcriptional arrest via a Top1-indepenedent
mechanism, presumably via the ability of AP sites and
30dRP lesions to block progression of RNA polymerases.
Consistent with this, additional depletion of TDP1 in
Top1KD cells led to a similar reduction in transcription,
which was not restored to background levels during
MMS-free recovery periods. We conclude from these ex-
periments that TDP1 promotes transcription recovery
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Figure 3. Overexpression of TDP1 protects human cells from MMS-induced DNA damage. (a) MRC5 cells were transfected with an empty mam-
malian expression vector ‘Vector’, or constructs encoding Flag-APE1, Myc-TDP1 or both. Expression of fusion proteins was analyzed by
fractionating cell lysates using SDS–PAGE and immunoblotting, using anti-TDP1 (Eurogentec), anti-APE1 (Novus) or anti-tubulin (Sigma)
antibodies. (b) MRC5 ectopically expressing Flag-APE1, Myc-TDP1 or both was incubated with the indicated concentrations of MMS and per-
centage survival calculated from three independent replicates. Data are the mean±s.e.m. Asterisks denote statistical difference (P< 0.01;t-test)
between cells overexpressing APE1 alone and cells expressing both APE1 and TDP1.
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following MMS and suggest that this is due to its AP/
30-dRP lyase activity.
To what extent do TDP1’s phosphodiesterase and lyase
activities contribute to the protective effect from MMS?
As both activities use the same active site (17), it was
difﬁcult to generate a separation-of-function mutant. We
reasoned that eliminating the contribution of TDP1
phosphodiesterase activity on MMS-induced Top1-
breaks by depleting Top1, coupled with limiting APE1
lyase function, would allow us to directly examine the
lyase role of TDP1. Any sensitization induced by TDP1
knockdown in this system would be due to its lyase and
not phosphodiesterase activity. Pharmacological inhib-
ition of APE1 or its siRNA-mediated depletion sensitized
Top1KD cells to MMS (Figure 7a, b), reﬂecting the im-
portance of APE1 lyase to protect from MMS.
Importantly, additional depletion of TDP1 led to
marked sensitization (compare open and closed circles
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Figure 4. Depletion of Top1 protects human cells from camptothecin-induced cell death. (a) Control ‘WT’ or TDP1KD human MRC5 cells were
subjected to lentivirus particles containing control non-targeting shRNA or shRNA against human Top1 ‘Top1KD’ to generate stable cells in which
TDP1 or Top1 was depleted separately or together. Cell lysates were fractionated by SDS–PAGE and analyzed by immunoblotting using anti-TDP1
or anti-Top1 antibodies. (b) The indicated cell lines were incubated with 20 mM CPT for 1 h at 37C and DNA strand breakage quantiﬁed using
alkaline comet assays. Average tail moments from 50 cells/sample were measured, and data are the average±s.e.m. of three independent experi-
ments. (c) The indicated MRC5 cells were incubated with increasing concentrations of CPT for 60min at 37C and survival was determined from
three biological replicates and presented as mean±s.e.m. (d) Cells were additionally subjected to control siRNA or Top1 siRNA to deplete residual
levels of Top1 in TDP1KD/Top1KD cells and cell lysate analyzed by SDS–PAGE and immunoblotting. (e) Control ‘WT’, TDP1KD, Top1KD or
TDP1KD/Top1KD cells in which Top1 level was additionally depleted by siRNA were treated with increasing concentrations of CPT for 60min at
37C and survival determined from three biological replicates and presented as mean±s.e.m. Asterisks denote statistical difference (P< 0.05; t-test)
between TDP1KD and TDP1KD Top1KD cells.
Nucleic Acids Research, 2014, Vol. 42, No. 5 3095
 at U
niversity of Sussex on June 18, 2014
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Figure 7a, b). Together these observations suggest a role
for TDP1 lyase in response to MMS damage, particularly
at conditions where APE1 is limiting.
To further dissect the mechanisms by which TDP1
protects from MMS damage, we exploited our
observations in chicken DT40 cells where inhibition of
Poly (ADP-ribose) polymerase (PARP) activity did
not further sensitize Tdp1/ cells to Top1 poisons
(Figure 8a). Inhibition of PARP has been shown to
impair DNA SSB repair due to trapping of the enzyme
at repair intermediates, physically blocking subsequent
repair events (30). We reasoned that if the cytotoxicity
of TDP1-deﬁcient cells to MMS is mediated solely via
Top1-breaks then PARP inhibition would not confer add-
itional sensitization, as is the case for Top1 poisons. In a
remarkable contrast to this proposition, Tdp1/ cells
treated with the PARP inhibitor Olaparib were signiﬁ-
cantly more sensitive to MMS than untreated cells
(Figure 8b). This was also conﬁrmed in human MRC5
cells in which TDP1 levels were stably depleted using
shRNA (Figure 8c). These data suggest that PARP
and TDP1 operate together to repair Top1-breaks but
independently to repair AP/dRP breaks (Figure 8d).
Finally, to examine whether the involvement of TDP1 in
MMS damage could be applied to improve alkylation-
based chemotherapy, we screened a panel of cancer cell
lines for TDP1 expression. We identiﬁed RKO and
DLD1 colorectal cancer cells that express remarkably dif-
ferent levels of TDP1 (Figure 9a, left) and then compared
their ability to survive MMS damage. Consistent with our
data, DLD1 cells were more sensitive than RKO to MMS
(Figure 9a, right). This hypersensitivity was not due to
different levels of APE1 or Top1 (Figure 9a) and was not
due to the non-isogenic nature of the two cell lines, as
depletion of TDP1 using siRNA in RKO also led to
marked sensitization to MMS (Figure 9b). Alkylation-
based chemotherapy such as Temozolomide (TMZ) are
widely used to treat a variety of human cancers, most
notably Glioblastoma Multiforme (GM), which is the
most common aggressive adult primary tumor of the
central nervous system. TMZ delivers a methyl group to
purine bases of DNA, resulting in O6-methyl guanine,
N7-methyl guanine and N3-methyl adenine. The primary
cytotoxic lesion is believed to be O6-methyl guanine, which
can be removed by a direct repair mechanism mediated by
methylguanine methyltransferase (MGMT). Inherent and
acquired resistance to TMZ viaMGMT expression present
major obstacles in the clinical management of GM. In light
of the data presented above, we reasoned that reducing
TDP1 levels might offer a new tool to sensitize TMZ-
resistant GM cells to alkylation damage. Consistent with
previous work (31), T98G GM cells expressing MGMT
exhibited signiﬁcantly higher levels of resistance to TMZ
than U87 cells that express undetectable levels of MGMT
(Figure 9c). Depletion of TDP1 or the additional depletion
of APE1 led to marked sensitization of T98G cells to TMZ
(Figure 9d), suggesting the importance of determining
and/or manipulating TDP1 expression levels to improve
the clinical outcome of TMZ-based chemotherapy.
DISCUSSION
Accumulating evidence suggest that human cells use distinct
but functionally overlapping pathways to handle the en-
dogenous and external load of DNA damage. As cancer
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Figure 5. Depletion of Top1 protects human cells from alkylation-
induced DNA damage. (a) Control ‘WT’, TDP1KD, Top1KD or
TDP1KD/Top1KD double mutant cells in which Top1 level was add-
itionally depleted by siRNA were incubated with increasing concentra-
tions of MMS for 15min at 37C. Survival was determined from three
biological replicates and presented as mean±s.e.m. Top1 depletion
protects TDP1KD from MMS damage (Asterisks; P< 0.05; t-test
between TDP1KD ‘closed circles’ and TDP1KD Top1KD cells ‘closed
squares’). This protection did not fully restore resistance to levels
observed in Top1KD cells (Stars; P< 0.01; t-test between Top1KD
‘open squares’ and TDP1KD Top1KD cells ‘closed squares’), suggesting
that a proportion of MMS-induced breaks are processed by TDP1 in a
Top1-independent manner. (b) Human MRC5 cells were incubated with
20 mM CPT or with 2 mg/ml MMS for 3 h at 37C and cell lysate
fractionated by SDS–PAGE and analyzed by immunoblotting.
(c) MRC5 cells were incubated with DMSO or 50 mM 5,6-dichloro-1-
b-D-ribofuranosylbenzimidazole ‘DRB’ for 1 h or with 1 mg/ml
a-amanitin for 16 h followed by an additional 3 h incubation with
2mg/ml MMS. Cell lysates were fractionated by SDS–PAGE and
analyzed by immunoblotting.
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Figure 6. TDP1 promotes transcription recovery following alkylation-induced DNA damage. (a) Control MRC5 cells ‘WT’ grown on coverslips
were maintained for 2 days in serum-free media, treated with DMSO ‘Mock’ or with 20 mM CPT ‘CPT’ for 1 h and either harvested immediately after
treatment or incubated in CPT-free media for a subsequent 3 h to allow for transcription recovery. Cells were incubated with 0.1mM 5-ethynl uridine
(EU) for 30min to label newly synthesized RNA, which was visualized by using the Click iT reaction with Alexa Flour azide 488. EU-labeled RNA
was subjected to immunoﬂuorescence analyses and DNA counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Representative micrographs are
depicted. (b) TDP1KD or Top1KD MRC5 cells were examined for nascent RNA synthesis as described in (a). (c) Average ﬂuorescence signal
(arbitrary units ‘AU’) from 200 to 300 cells as described in (a) and (b) were quantiﬁed from three biological replicates± s.e.m. (d) The indicated
MRC5 cells were grown in serum-free medium and treated with 2mg/ml MMS for 15min at 37C. Cells were either harvested immediately after
treatment ‘MMS’ or incubated in MMS-free media for a subsequent 1 h ‘R’. Newly synthesized RNA was quantiﬁed and average ﬂuorescence signal
of EU-labeled RNA was quantiﬁed as described earlier from three biological replicates.
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cells are often perturbed in many DNA repair pathways
(32), understanding the complexity of functional redun-
dancy is key in exploiting the inherent biological variations
in cancer. This study reveals a synergistic sensitivity of cells
depleted for TDP1 and APE1 to alkylating agents, raising
the possibility that TDP1 inhibitors could selectively target
tumors with perturbed APE1 expression. In addition, the
administration of alkylating agents in cancer cells in which
TDP1 is inherently deﬁcient, or in combination with TDP1
inhibitors, may also provide a new anti-cancer strategy to
target speciﬁc class of tumors, particularly those that are
resistant to alkylation damage such as temozolomide-resist-
ant GM. In contrast to APE1 inhibition, TDP1 suppression
is a more attractive tool, as it is predicted to provide a better
tolerance during chemotherapy. This is suggested by gene
knockout experiments in vertebrate systems where TDP1
deletion, unlike that of APE1, is not essential for organismal
survival (33–35).
TDP1 was ﬁrst identiﬁed as an activity in S. cerevisiae
that is capable of cleaving the covalent phosphodiester
linkage between a tyrosine residue in Top1 and
30-phosphate on DNA (36). This type of DNA linkage is
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Figure 7. Depletion of TDP1 sensitizes Top1KD/APE1KD cells to alkylation-induced DNA damage. (a) Top1KD cells were subjected to control
siRNA or siRNA for TDP1 or APE1, separately or together and cells were incubated with increasing concentrations of MMS for 15min at 37C.
Survival was determined from three biological replicates and presented as mean±s.e.m. Asterisks; P< 0.05; t-test between Top1KD/TDP1KD ‘open
circles’ and Top1KD/TDP1KD/APE1KD ‘closed circles’. (b) Lysates from cells described in ‘a’ were fractionated by SDS–PAGE and analyzed by
immunoblotting. (c) Top1KD or Top1KD/TDP1KD cells were incubated with DMSO or 150mM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h
followed by an additional incubation with the indicated concentrations of MMS for 15min at 37C. Cell survival was calculated from the average of
three independent experiments (two biological replicates)± s.e.m. Asterisks denote statistical difference (P< 0.05; t-test) between APEi treated
Top1KD and Top1KD/TDP1KD cells. (d) Lysates from cells described in ‘c’ were fractionated by SDS–PAGE and analyzed by immunoblotting.
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typically formed during abortive Top1 reactions and
further work has shown that TDP1 protects mammalian
cells from Top1-mediated DNA damage (33,37). The
30-leaving group does not seem to be restricted on
tyrosine because biochemical studies reported a decent
activity of TDP1 on 30-phosphoglycolate (38), AP site
mimics (17,39) and 30-dRP (15,16). The 30-dRP lyase
activity has been reported for human and S. pombe TDP1
where, in the latter, it presents the major APE1-independ-
ent activity. It is likely that TDP1 AP/dRP lyase is more
important in yeast than in human due to the lack of NEIL
proteins in yeast, which provide an extra layer of redun-
dancy in dealing with AP sites in human cells (40).
However, experiments in DT40 cells (15) and our
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Figure 8. The PARP inhibitor Olaparib sensitizes TDP1-deﬁcient cells to alkylation damage but not Top1 poisons. (a) Chicken DT40 Tdp1/ cells
were stably transfected with an empty mammalian expression vector ‘Vector’ or with a construct expressing human Myc-TDP1 ‘hTDP1’. Cells were
pre-incubated with 0.5 mM of the PARP inhibitor Olaparib for 1 h at 39C followed by additional incubation of the indicated concentrations of CPT
for 72 h at 39C. Viability was determined by quantifying ﬂuorescence signals using CellTiter-Blue. Viability of untreated cells was set to 100% and
error bars represent standard error from three independent biological repeats. Inset: DT40 cell lysate fractionated by SDS–PAGE and analyzed by
anti-Myc (9B11; Cell signaling) and anti-PCNA (PC10) immunoblotting. Asterisks denote statistical differences (P> 0.1; t-test) between Vector alone
‘open squares’ and Vector+Olaparib ‘closed squares’ (b) Viability of the indicated DT40 cells was analyzed in presence or absence of Olaparib as
described earlier in text, following incubation with the indicated concentrations of MMS for 72 h. Data are the average of three independent
repeats± s.e.m. Asterisks denote statistical differences (P< 0.02; t-test) between Vector alone ‘open squares’ and Vector+Olaparib ‘closed
squares’ Inset: survival curves as described earlier in the text following incubation with a lower dose range of MMS (c) WT and TDP1KD
human MRC5 cells were pre-incubated with 1mM Olaparib for 60min followed by additional incubation with the indicated concentrations of
MMS for 15min at 37C. Survival was determined from three independent repeats and data are the average±s.e.m. Asterisks denote statistical
differences (P< 0.01, t-test) between TDP1KD ‘open squares’ and TDP1KD+Olaparib ‘closed squares’ (d) Model for the repair of alkylation-induced
DNA damage by TDP1. Base damage induces both Top1- and AP/3’-dRP DNA breaks. The former are dealt with TDP1 in a PARP-dependent
process, whereas the latter are processed in a PARP-independent mechanism. PARP activity appears to promote TDP1 alternative pathways in
response to alkylation damage, which likely involves canonical base excision repair factors such as APE1.
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Figure 9. TDP1 depletion sensitizes glioblastoma-resistant cancer cells to temozolomide. (a) Cell lysates from RKO and DLD1 cancer cell lines were
fractionated by SDS–PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz), anti-Tubulin (Abcam) and
anti-APE1 (Novus) antibodies (left). RKO and DLD1 cells were compared for their survival following exposure with the indicated doses of MMS for
15min at 37C (right). Data are the average of three independent experiments± s.e.m. Where not visible, error bars are smaller than the symbol.
(b) RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left).
Control RKO (RKOSc siRNA) and RKO cells in which TDP1 levels were depleted (RKOTDP1 siRNA) were examined for their survival following
exposure to the indicated doses of MMS, as described earlier in the text (right). (c) Glioblastoma multiforme T98G and U87 cancer cell lines were
analyzed for methylguanine methyltransferase (MGMT) expression using anti-MGMT antibodies (Abcam) (left). High-MGMT expressing T98G cells
were compared with low-MGMT expressing U87 cells for their survival following exposure to increasing concentrations of the alkylating agent
temozolomide (right). (d) TG98 cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by
immunoblotting (left). Control T98G cells (T98GSc siRNA) and cells in which TDP1 levels were depleted (TG98TDP1 siRNA) were incubated with
DMSO or 150 mM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h followed by additional incubation with the indicated concentrations of MMS
for 15min at 37C. Cell survival was blindly scored from three independent biological repeats, and data are the average±s.e.m. (right). (e) Model
for the repair of temozolomide-induced DNA breaks. Temozolomide delivers a methyl group to purine bases of DNA, resulting in O6-methyl
guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a
direct repair mechanism mediated by methylguanine methyltransferase (MGMT). Inherent and acquired resistance to temozolomide via MGMT
expression presents a major challenge in cancer therapy, particularly for glioblastoma multiforme. TDP1 promotes the repair of methylated purines
induced by temozolomide via a distinct non-canonical BER pathway. Increasing the load of unrepaired methylated purines by exploiting the limited
availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical
outcome of temozolomide-based cancer therapy. Asterisks denote statistical differences (P< 0.05; t-test) between control and TDP1-deﬁcient cells.
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observations here, showing a protective role of TDP1 inde-
pendently of Top1 suggest a role for its lyase activity in
human cells. Thus, despite its weaker activity on AP/dRP
compared with canonical 30-phosphotyrosyl substrates
(15), we suggest that TDP1 AP/dRP lyase has a role in
human cells, particularly if APE1 is limiting.
In addition to their use in the clinic to kill cancer
cells, alkylation damage is almost unavoidable and it is
intriguing to speculate that the progressive accumulation
of AP/30-dRP lesions may also contribute to neurological
decline observed in TDP1-deﬁcient patients with
spinocerebellar ataxia with axonal neuropathy (SCAN1)
(41). Accumulation of Top1-breaks during transcription
has been associated with the neurological decline in
SCAN1 and in other cerebellar degenerative hereditary
disorders such as ataxia telangiectasia (42). However, the
Top1-independent nature of transcriptional decline
observed here (Figure 6d) suggests that the role of TDP1
during transcription in response to base damage is likely
due to its lyase rather than its tyrosyl DNA phospho-
diesterase activity.
One of the important observations of the current
study is the demonstration that Top1 depletion protects
mammalian cells from alkylation damage. Biochemical
analyses have shown that Top1 can be trapped by a
variety of endogenous DNA lesions including AP sites
and strand breaks (43,44). Lethal DNA double-strand
breaks (DSBs) can be generated by replication runoff of
Top1-SSBs during S-phase, which likely contributes to
the cell killing observed in this study following MMS.
It is thus possible that in addition to its 30-dRP/AP lyase
(16,45) human TDP1 can protect from base damage via its
ability to disjoin Top1 peptides from DNA. Intriguingly,
the former activity appears to be PARP independent, as
PARP inhibition further sensitized TDP1-deﬁceint cells to
MMS, whereas it did not for CPT. It is likely that PARP
and TDP1 function together in the same pathway to limit
DSB formation and replication runoff following Top1
poisoning (46). We propose a model where PARP
activity coordinates fork stabilization with the removal
of stalled Top1 peptide from DNA termini by TDP1.
This dual action of PARP may provide sufﬁcient time to
repair Top1-breaks by slowing or reversing the forks while
promoting the resolution of Top1-breaks and preventing
DSB formation. On the other hand, PARP inhibitors may
trap PARP on a subset of MMS-induced repair intermedi-
ates, uncoupling them from subsequent repair and
generating toxic lesions at replication forks that are
distinct from those processed by TDP1 (47), thereby
causing synergistic lethality. It is possible that the latter
breaks are sufﬁciently different in origin, structure or ac-
cessibility to repair than those processed by PARP-related
mechanisms and that enzymes acting on them are
somehow excluded from acting on the other distinct
class of breaks. Much remains to be determined on how
these two pathways are prioritized in cells and whether
one pathway predominates under particular circum-
stances. Nevertheless, these observations provide a new
mechanistic rationale for the synergy of combining
PARP inhibitors and Top1 poisons in clinical trials
(46,48) and suggest the limited clinical utility of TDP1 in
this context but highlights its potential importance during
PARP inhibitor and TMZ combined therapy.
In summary, these data demonstrate a role for TDP1
in response to alkylation damage in human cells and
illustrates the potential application of this knowledge to
improve alkylation-based cancer therapy. TDP1 promotes
the repair of both Top1- and AP/30-dRP breaks induced
by alkylating agents via its tyrosyl DNA phosphodiester-
ase and AP/30dRP lyase activities. Although the former is
PARP dependent the latter is PARP independent, opening
new treatment paradigms for the emerging clinical appli-
cations of PARP inhibitors.
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